The low-cost Lumasonix Blood Test (LBT) provides crucial information about otherwise undetectable cancer tumors, enabling early diagnosis that improves the longevity and quality of life for cancer patients.

The treatment of cancers detected at later stages proves difficult, often futile and imposes huge emotional and economic costs. Early detection, by annual screening of the general population for all cancers, it is the single most important change that will positively impact clinical outcomes.

Lumasonix Inc. logo



Event details

Date: September 14 - 16, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


16 in total